Ken Griffin Soleno Therapeutics Inc Transaction History

Citadel Advisors LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$0.14 - $0.23 $21,096 - $34,658	150,689 Added 104.19%	295,312 $55,000
Q1 2022 May 16, 2022	SELL	$0.22 - $0.47 $1,155 - $2,468	-5,253 Reduced 3.5%	144,623 $32,000
Q4 2021 Feb 14, 2022	SELL	$0.41 - $0.91 $3,310 - $7,348	-8,075 Reduced 5.11%	149,876 $61,000
Q3 2021 Nov 15, 2021	BUY	$0.8 - $1.12 $10,458 - $14,641	13,073 Added 9.02%	157,951 $146,000
Q2 2021 Aug 16, 2021	BUY	$0.97 - $1.32 $79,529 - $108,225	81,989 Added 130.37%	144,878 $165,000
Q1 2021 May 17, 2021	BUY	$1.24 - $3.3 $52,766 - $140,428	42,554 Added 209.26%	62,889 $79,000
Q4 2020 Feb 16, 2021	BUY	$1.61 - $2.23 $9,220 - $12,771	5,727 Added 39.2%	20,335 $39,000
Q3 2020 Nov 16, 2020	BUY	$1.71 - $2.51 $24,979 - $36,666	14,608 New	14,608 $37,000
Q2 2019 Aug 14, 2019	SELL	$1.93 - $2.95 $34,585 - $52,864	-17,920 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$1.35 - $2.68 $6,741 - $13,383	4,994 Added 38.64%	17,920 $0
Q2 2018 Aug 10, 2018	BUY	$1.56 - $3.1 $20,164 - $40,070	12,926 New	12,926 $0

Ticker SLNO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 8,101,250
Market Cap $441M
Description
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing P...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.